跳至主要内容
临床试验/2024-511867-27-00
2024-511867-27-00招募中3 期

Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes (IMPACT-1D)

Assistance Publique Hopitaux De Paris1 个研究点 分布在 1 个国家目标入组 230 人开始时间: 2024年9月10日最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
230
试验地点
1
主要终点
Difference between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.

研究概览

简要总结

To show that metformin, patients with type 1 diabetes but without chronic kidney disease, is able to slow below- knee arterial calcification

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Type 1 diabetes
  • Women and Men ≥ 18 years old and ≤ 80 years old with: *Complications: -diabetic retinopathy and/or -nephropathy (with creatinine clearance ≥ 60 mL/mn) and/or -neuropathy and/or -peripheral arterial occlusive disease and/or -cardiopathy and/or -stroke and/or *cardiovascular risk factors - hypertension and/or - dyslipidemia (HDL < 0.35g/L or LDL > 1.9g/L or treated dyslipidemia) and/or - tobacco use (old or active smoking greater than 5 pack years) and/or *Diabetes duration >20 years
  • For women in childbearing age, effective contraception during the whole trial
  • Signed written informed consent
  • Affiliation of a social security regime (patient with AME cannot be included)

排除标准

  • Creatinine clearance of less than 3 months <60 mL/mn (MDRD) at the inclusion time
  • Patient under legal protection measure (tutorship or curatorship) or deprived of freedom or under measure of safety
  • Unable to consent
  • Known metformin contra-indication: • severe liver insufficiency –CHILD B or C • heart failure (FEVG<45%) or • history of pulmonary oedema, respiratory insufficiency with history of acute respiratory failure or patients receiving oxygen therapy • chronic ethylism • lactic acidosis
  • Known hypersensitivity to metformin or to any of its excipients or placebo excipients (lactose)
  • Indication or history of lower limb angioplasty (with stenting) and/or bypass
  • Previous treatment with metformin (within 3 months prior to inclusion)
  • HbA1c of less than 3 months >11%
  • Chronic inflammatory disease or chronic immune-suppressive drugs intake
  • Participation in an another interventional trial (Jardé 1 and 2) or in the exclusion period of any other interventional study
  • Pregnancy woman (confirmed by a sanguine beta-HCG test) or breastfeeding woman

结局指标

主要结局

Difference between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.

Difference between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.

次要结局

  • Difference between below-knee arterial ultrasonographic occlusion score at T0 and T2years in type 1 diabetic patients supplemented or not with metformin.
  • Difference between ankle and toe brachial indexes at T0 and T2years in type 1 diabetic patients supplemented or not with metformin.
  • Difference between pulse wave velocity at T0 and T2 years in type 1 diabetic patients supplemented or not with metformin.
  • Difference between coronary calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.
  • Difference between below-knee arterial calcification score progression between T0 and T2years in type 1 diabetic patients treated or not with metformin and with initial below-knee arterial calcification score ≤ and >400.

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Coordinating Investigator

Scientific

Assistance Publique Hopitaux De Paris

研究点 (1)

Loading locations...

相似试验